Skip to main content

Table 3 Clinical summary of patients with Tolosa-Hunt Syndrome

From: The clinical features and outcomes of Tolosa-Hunt syndrome

Case Sex Age Clinical findings Involved CN MRI findings ESR
(0–20)
CRP
(0–5)
Treatment
(per day)
Relapse
1 M 73 Diplopia 6 CN Enhanced left cavernous sinus and clinoid process 15 0.9 Oral MPD 50 mg -
2 M 74 Diplopia, Ptosis Optic nerve, 3/4/6 CN Enlarged and enhanced left cavernous sinus/apex/optic nerve 52 2.6 Oral MPD 50 mg 5 weeks interval
3 M 52 Diplopia Optic nerve, 4 CN Mild thickening and enhanced right cavernous sinus/apex (superior/inferior orbital fissure) 10 2.5 IV MPD 1 g -
4 F 46 Diplopia, Ptosis 3/4/6 CN Enhanced focal triangular shaped right cavernous sinus with enlarged right superior ophthalmic vein 21 0.3 IV MPD 1 g -
5 M 68 Diplopia, Ptosis 3 CN Enhanced focal right superior orbital fissure 12 2.0 Oral MPD 50 mg 5 years ago
6 M 46 Diplopia 6 CN Slightly bulging of right cavernous sinus 2 0.5 Oral MPD 50 mg -
7 M 46 Diplopia 6 CN, facial nerve Suspicious enhanced left superior orbital fissure 10 0.7 Oral MPD 50 mg -
8 M 69 Diplopia 4 CN Enhanced left cavernous sinus/superior orbital fissure 8 0.8 Oral MPD 50 mg -
9 M 78 Diplopia, Ptosis 3/6 CN Enlarged and enhanced left cavernous sinus 11 0.7 IV MPD 1 g -
10 F 42 Diplopia, Ptosis 3/4/6 CN Enhanced right cavernous sinus and extending to orbital apex 30 0.5 IV MPD 1 g -
11 M 35 Diplopia Trigeminal nerve, 6 CN Enhanced left cavernous sinus and extracranial portion of mandibular division of trigeminal nerve 13 1.1 IV MPD 1 g -
  1. MRI = magnetic resonance imaging; ESR = erythrocyte sedimentation rate; CRP = C-reactive protein
  2. CN = cranial nerve; MPD = methylprednisolone; IV = intravenous